PT - JOURNAL ARTICLE AU - Iourov, Ivan Y AU - Zelenova, Maria A AU - Vorsanova, Svetlana G TI - COVID-19: a crash test for biomedical publishing? AID - 10.1101/2020.06.13.20130310 DP - 2020 Jan 01 TA - medRxiv PG - 2020.06.13.20130310 4099 - http://medrxiv.org/content/early/2020/06/16/2020.06.13.20130310.short 4100 - http://medrxiv.org/content/early/2020/06/16/2020.06.13.20130310.full AB - The effect of COVID-19 on biomedical publishing (BP) (i.e. scientific biomedical periodicals continuously published by research communities or commercial publishers) has not been deeply explored. To estimate the immediate COVID-19 impact on BP, we have assessed PubMed-indexed articles about COVID-19 (PMIAC) from December 2019 to April 2020. PMIAC have been classified according to publication date, country, and journals for evaluation of time-, region- and scientometric-dependant impact of COVID-19 on BP and have been curated manually (i.e. each entry has been individually analyzed). PMIAC analysis reflects geographic and temporal parameters of outbreak spread. A major BP problem is related to the fact that only 40% of articles report/review/analyze data. Another BP weakness is the clusterization of “highly-trusted” publications according to countries of origin and “highly impacting” journals. Finally, a problem highlighted by COVID-19 crisis is the increased specification of biomedical research. To solve the problem, analytical reviews integrating data from different areas of biology and medicine are required. The data on PMIAC suggest priority of “what is published” over “where it is published” and “who are the authors”. We believe that our brief analysis may help to shape forthcoming BP to become more effective in solving immediate problems resulted from global threats.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNot applicableFunding StatementACKNOWLEDGMENTS Authors are partially supported by RFBR and CITMA according to the research project No. 18-515-34005. Prof. IY Iourov is supported by the Government Assignment of the Russian Ministry of Science and Higher Education, Assignment no. AAAA-A19-119040490101-6. Prof. SG Vorsanova is supported by the Government Assignment of the Russian Ministry of Health, Assignment no. AAAA-A18-118051590122-7.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is the analysis of bibliographic data published in peer-reviewed periodicals indexed in publicly accessible databases. No patients are involved in this study. Accordingly, there is no need for specific clinical trial registration, ethics committee approvals or related actions.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data is provided in the manuscript.